Survival after withdrawal of dofetilide in patients with congestive heart failure and a short baseline QTc interval: A follow-up on the Diamond-CHF QT substudy

European Heart Journal

Volumn 24, Issue 3, 2003, Pages 274-279

  Brendorp, B ^a,b   Torp Pedersen, C ^a   Elming, H ^a   Kober L ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet ^*  (Denmark)

Author keywords

Antiarrhythmic agents; Heart failure; Prognosis; QT interval

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOFETILIDE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NERVE; PRIORITY JOURNAL; PROGNOSIS; QT INTERVAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SINUS RHYTHM; SURVIVAL; TREATMENT OUTCOME; VALIDATION PROCESS;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; INFANT, NEWBORN; LONG QT SYNDROME; MALE; MIDDLE AGED; PHENETHYLAMINES; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SULFONAMIDES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0037322862     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(02)00427-X     Document Type: Article

References (9)

1. Singh SN, Fletcher RD, Fisher SG et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival trial of antiarrhythmic therapy in congestive heart failure. N Engl J Med 1995;333:77-82.
2. Waldo AL, Camm AJ, deRuyter H et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996;348:7-12.
3. Julian DG, Camm AJ, Frangin G et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997;349:667-74.
4. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Danish investigations of arrhythmia and mortality ON dofetilide. Clin Cardiol 1997;20:704-10.
5. Torp-Pedersen C, Moller M, Bloch-Thomsen PE et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999;341:857-65.
6. Rasmussen HS, Allen MJ, Blackburn KJ et al. Dofetilide, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol 1992;20(Suppl 2):S96-S105.
7. Brendorp B, Elming H, Jun L et al. QTc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. Circulation 2001;103:1422-7.
8. Hohnloser SH, Singh BN. Proarrhythmia with class III anti-arrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 1995;6:920-36.
9. Haverkamp W, Breithardt G, Camm AJ et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Eur Heart J 1995;21:1216-31.